JP2021534124A - 癌治療用ｐｔｐｎ１１（ｓｈｐ２）阻害剤としての６−（４−アミノ−３−メチル−２−オキサ−８−アザスピロ［４．５］デカン−８−イル）−３−（２，３−ジクロロフェニル）−２−メチルピリミジン−４（３ｈ）−オン誘導体及び関連化合物 - Google Patents

癌治療用ｐｔｐｎ１１（ｓｈｐ２）阻害剤としての６−（４−アミノ−３−メチル−２−オキサ−８−アザスピロ［４．５］デカン−８−イル）−３−（２，３−ジクロロフェニル）−２−メチルピリミジン−４（３ｈ）−オン誘導体及び関連化合物 Download PDF

Info

Publication number
JP2021534124A
JP2021534124A JP2021506929A JP2021506929A JP2021534124A JP 2021534124 A JP2021534124 A JP 2021534124A JP 2021506929 A JP2021506929 A JP 2021506929A JP 2021506929 A JP2021506929 A JP 2021506929A JP 2021534124 A JP2021534124 A JP 2021534124A
Authority
JP
Japan
Prior art keywords
group
alkyl
amino
halo
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021506929A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534124A5 (enExample
Inventor
ジョーンズ フィリップ
チャコ バーバラ
エル．キャロル クリストファー
マンダル ピジャス
クロス ジェイソン
Original Assignee
ナビール ファーマ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナビール ファーマ，インコーポレイティド filed Critical ナビール ファーマ，インコーポレイティド
Publication of JP2021534124A publication Critical patent/JP2021534124A/ja
Publication of JP2021534124A5 publication Critical patent/JP2021534124A5/ja
Priority to JP2023132960A priority Critical patent/JP7579402B2/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021506929A 2018-08-10 2019-08-09 癌治療用ｐｔｐｎ１１（ｓｈｐ２）阻害剤としての６−（４−アミノ−３−メチル−２−オキサ−８−アザスピロ［４．５］デカン−８−イル）−３−（２，３−ジクロロフェニル）−２−メチルピリミジン−４（３ｈ）−オン誘導体及び関連化合物 Ceased JP2021534124A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023132960A JP7579402B2 (ja) 2018-08-10 2023-08-17 癌治療用ｐｔｐｎ１１（ｓｈｐ２）阻害剤としての６－（４－アミノ－３－メチル－２－オキサ－８－アザスピロ［４．５］デカン－８－イル）－３－（２，３－ジクロロフェニル）－２－メチルピリミジン－４（３ｈ）－オン誘導体及び関連化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862717588P 2018-08-10 2018-08-10
US62/717,588 2018-08-10
US201862773921P 2018-11-30 2018-11-30
US62/773,921 2018-11-30
PCT/US2019/045903 WO2020033828A1 (en) 2018-08-10 2019-08-09 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023132960A Division JP7579402B2 (ja) 2018-08-10 2023-08-17 癌治療用ｐｔｐｎ１１（ｓｈｐ２）阻害剤としての６－（４－アミノ－３－メチル－２－オキサ－８－アザスピロ［４．５］デカン－８－イル）－３－（２，３－ジクロロフェニル）－２－メチルピリミジン－４（３ｈ）－オン誘導体及び関連化合物

Publications (2)

Publication Number Publication Date
JP2021534124A true JP2021534124A (ja) 2021-12-09
JP2021534124A5 JP2021534124A5 (enExample) 2022-08-18

Family

ID=67766350

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021506929A Ceased JP2021534124A (ja) 2018-08-10 2019-08-09 癌治療用ｐｔｐｎ１１（ｓｈｐ２）阻害剤としての６−（４−アミノ−３−メチル−２−オキサ−８−アザスピロ［４．５］デカン−８−イル）−３−（２，３−ジクロロフェニル）−２−メチルピリミジン−４（３ｈ）−オン誘導体及び関連化合物
JP2023132960A Active JP7579402B2 (ja) 2018-08-10 2023-08-17 癌治療用ｐｔｐｎ１１（ｓｈｐ２）阻害剤としての６－（４－アミノ－３－メチル－２－オキサ－８－アザスピロ［４．５］デカン－８－イル）－３－（２，３－ジクロロフェニル）－２－メチルピリミジン－４（３ｈ）－オン誘導体及び関連化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023132960A Active JP7579402B2 (ja) 2018-08-10 2023-08-17 癌治療用ｐｔｐｎ１１（ｓｈｐ２）阻害剤としての６－（４－アミノ－３－メチル－２－オキサ－８－アザスピロ［４．５］デカン－８－イル）－３－（２，３－ジクロロフェニル）－２－メチルピリミジン－４（３ｈ）－オン誘導体及び関連化合物

Country Status (32)

Country Link
US (3) US11104675B2 (enExample)
EP (2) EP3833670B1 (enExample)
JP (2) JP2021534124A (enExample)
KR (1) KR102707409B1 (enExample)
CN (1) CN112601750B (enExample)
AU (1) AU2019319971B2 (enExample)
BR (1) BR112021002327A2 (enExample)
CA (1) CA3109181A1 (enExample)
CL (1) CL2021000355A1 (enExample)
CO (1) CO2021003074A2 (enExample)
CR (1) CR20210132A (enExample)
DK (1) DK3833670T3 (enExample)
ES (1) ES2981592T3 (enExample)
FI (1) FI3833670T3 (enExample)
HR (1) HRP20240861T1 (enExample)
HU (1) HUE067297T2 (enExample)
IL (2) IL307361B2 (enExample)
LT (1) LT3833670T (enExample)
MX (2) MX2021001608A (enExample)
PE (1) PE20211050A1 (enExample)
PH (1) PH12021550268A1 (enExample)
PL (1) PL3833670T3 (enExample)
PT (1) PT3833670T (enExample)
RS (1) RS65728B1 (enExample)
SA (1) SA521421205B1 (enExample)
SG (1) SG11202100199UA (enExample)
SI (1) SI3833670T1 (enExample)
SM (1) SMT202400192T1 (enExample)
TW (1) TWI827646B (enExample)
UA (1) UA128559C2 (enExample)
WO (1) WO2020033828A1 (enExample)
ZA (1) ZA202101449B (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11466017B2 (en) 2011-03-10 2022-10-11 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
WO2017210134A1 (en) 2016-05-31 2017-12-07 Board Of Regents, University Of Texas System Heterocyclic inhibitors of ptpn11
EP3515916B1 (en) 2016-09-22 2023-06-07 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
TW202500565A (zh) 2016-10-24 2025-01-01 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
US11591336B2 (en) 2017-05-26 2023-02-28 D. E. Shaw Research, Llc Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
EP3687997A1 (en) 2017-09-29 2020-08-05 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
CN117263942A (zh) 2018-03-21 2023-12-22 传达治疗有限公司 Shp2磷酸酶抑制剂及其使用方法
US12138263B2 (en) 2018-03-21 2024-11-12 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof
KR102611661B1 (ko) 2018-05-02 2023-12-08 나비레 파르마, 인코퍼레이티드 Ptpn11의 치환된 헤테로사이클릭 억제제
PL3833670T3 (pl) 2018-08-10 2024-08-19 Navire Pharma, Inc. Pochodne 6-(4-amino-3-metylo-2-oksa-8-azaspiro[4.5]dekan-8-ylo)-3-(2,3-dichlorofenylo)-2-metylopirymidyn-4(3h)-onu oraz powiązane związki jako inhibitory ptpn11 (shp2) do leczenia raka
JP7337174B2 (ja) 2018-09-18 2023-09-01 ニカング セラピューティクス， インコーポレイテッド Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての三置換ヘテロアリール誘導体
AR117164A1 (es) 2018-11-30 2021-07-14 Merck Sharp & Dohme Derivados de amino-triazoloquinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso para el tratamiento de diversos tipos de cáncer
AU2019389168A1 (en) 2018-11-30 2021-06-24 Comet Therapeutics, Inc. Pantetheine derivatives and uses thereof
AU2020251841B2 (en) 2019-04-02 2025-01-30 Array Biopharma Inc. Protein tyrosine phosphatase inhibitors
CN113646049B (zh) * 2019-04-08 2024-08-13 默克专利有限公司 作为shp2拮抗剂的嘧啶酮衍生物
EP4034539A1 (en) 2019-09-24 2022-08-03 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of making and using the same
PH12022551102A1 (en) 2019-11-08 2023-11-20 Revolution Medicines Inc Bicyclic heteroaryl compounds and uses thereof
CN115916194A (zh) 2020-06-18 2023-04-04 锐新医药公司 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
EP4208261A1 (en) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
PE20240088A1 (es) 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras
IL308195A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors for cancer treatment
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
TW202313041A (zh) 2021-06-09 2023-04-01 瑞士商諾華公司 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
US20240374571A1 (en) 2021-09-01 2024-11-14 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
US20250009748A1 (en) 2021-09-30 2025-01-09 Navire Pharma, Inc. Combination therapy using substituted pyrimidin-4(3h)-ones and sotorasib
EP4408422A1 (en) 2021-09-30 2024-08-07 Navire Pharma, Inc. Combination therapy using a ptpn11 inhibitor and an egfr inhibitor
IL311957A (en) * 2021-10-06 2024-06-01 Bridgebio Services Inc Substituted pyrimidin-4(3h)-ones for use in treating cancer
CN118574621A (zh) * 2021-10-06 2024-08-30 美商纳维尔制药有限公司 取代的嘧啶-4(3h)-酮用于治疗癌症
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023205794A1 (en) 2022-04-22 2023-10-26 Bristol-Myers Squibb Company Combination therapy using a pyrimidone derivative as ptpn11 inhibitor and a pd-1/pd-l1 inhibitor and its use in the treatment of cancer
TW202404599A (zh) * 2022-04-22 2024-02-01 美商必治妥美雅史谷比公司 使用經取代之嘧啶-4(3h)-酮及納武單抗(nivolumab)之組合療法
EP4536364A1 (en) 2022-06-10 2025-04-16 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
CN121487951A (zh) 2023-04-07 2026-02-06 锐新医药公司 大环ras抑制剂
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
EP4695261A1 (en) 2023-04-14 2026-02-18 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
AU2024251341A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012011592A1 (ja) * 2010-07-23 2012-01-26 武田薬品工業株式会社 複素環化合物およびその用途
WO2017211303A1 (en) * 2016-06-07 2017-12-14 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
JP2018517746A (ja) * 2015-06-19 2018-07-05 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物および組成物
WO2018136264A1 (en) * 2017-01-23 2018-07-26 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004274403A1 (en) 2003-09-03 2005-03-31 Aventis Pharmaceuticals Inc. 5-aryl-Pyrazolo(4,3-d)pyrimidines, pyridines, and pyrazines and related compounds
KR100844864B1 (ko) 2004-02-27 2008-07-09 에프. 호프만-라 로슈 아게 헤테로아릴-융합 피라졸로 유도체
JP4790703B2 (ja) 2004-04-07 2011-10-12 武田薬品工業株式会社 環式化合物
AU2005309566A1 (en) 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or Rho kinase
GB0427604D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
GB0506147D0 (en) 2005-03-24 2005-05-04 Merck Sharp & Dohme Therapeutic agents
US20080153810A1 (en) 2006-11-15 2008-06-26 Forest Laboratories Holdings Limited Indazole derivatives useful as melanin concentrating receptor ligands
CA2677651A1 (en) 2007-02-15 2008-08-21 Novartis Ag Combinations of therapeutic agents for treating cancer
US8361959B2 (en) 2008-10-03 2013-01-29 Merck Sharp & Dohme Corp. Spiro-imidazolone derivatives as glucagon receptor antagonists
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
KR20110049217A (ko) 2009-11-04 2011-05-12 다우어드밴스드디스플레이머티리얼 유한회사 신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자
JP2011246389A (ja) 2010-05-26 2011-12-08 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有する縮環ピラゾール誘導体
USRE47009E1 (en) 2011-02-01 2018-08-28 The Children's Hospital Of Philadelphia HDAC inhibitors and therapeutic methods using the same
WO2013052263A2 (en) 2011-09-16 2013-04-11 Microbiotix, Inc. Antifungal compounds
WO2013040527A1 (en) 2011-09-16 2013-03-21 Microbiotix, Inc. Antimicrobial compounds
US9738610B2 (en) 2012-09-24 2017-08-22 Whitehead Institute For Biomedical Research Indazole derivatives and uses thereof
CA2944198C (en) 2013-04-26 2021-11-16 Indiana University Research & Technology Corporation Hydroxyindole carboxylic acid based inhibitors for oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (shp2)
WO2014200682A1 (en) 2013-05-24 2014-12-18 The Scripps Research Institute Bidentate-binding modulators of lrrk2 and jnk kinases
WO2015099481A1 (ko) 2013-12-27 2015-07-02 주식회사 두산 유기 전계 발광 소자
WO2015107494A1 (en) 2014-01-17 2015-07-23 Novartis Ag 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
ES2699351T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
KR101998435B1 (ko) 2014-06-09 2019-07-09 주식회사 두산 유기 전계 발광 소자
WO2016003917A1 (en) * 2014-07-03 2016-01-07 Quanticel Pharmaceuticals, Inc. Inhibitors of lysine specific demethylase-1
KR101708097B1 (ko) 2014-10-22 2017-02-17 주식회사 두산 유기 전계 발광 소자
WO2016151501A1 (en) 2015-03-25 2016-09-29 Novartis Ag Pharmaceutical combinations
WO2016203406A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
EP3310779B1 (en) 2015-06-19 2019-05-08 Novartis AG Compounds and compositions for inhibiting the activity of shp2
WO2017156397A1 (en) 2016-03-11 2017-09-14 Board Of Regents, The University Of Texas Sysytem Heterocyclic inhibitors of ptpn11
CN107286150B (zh) 2016-04-11 2020-07-07 中国科学院上海有机化学研究所 N-杂环类化合物、其中间体、制备方法、药物组合物和应用
WO2017210134A1 (en) 2016-05-31 2017-12-07 Board Of Regents, University Of Texas System Heterocyclic inhibitors of ptpn11
PT3468972T (pt) 2016-06-14 2020-08-21 Novartis Ag Compostos e composições para inibir a atividade da shp2
IL311645B2 (en) 2016-07-12 2025-11-01 Revolution Medicines Inc 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors
EP3515916B1 (en) 2016-09-22 2023-06-07 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
TW202500565A (zh) 2016-10-24 2025-01-01 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
CN110730678B (zh) 2017-01-10 2022-07-15 诺华股份有限公司 包含alk抑制剂和shp2抑制剂的药物组合
CN110446709B (zh) 2017-01-23 2023-09-12 锐新医药公司 作为变构shp2抑制剂的二环化合物
SG11201908820VA (en) 2017-03-23 2019-10-30 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
US11591336B2 (en) 2017-05-26 2023-02-28 D. E. Shaw Research, Llc Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
TWI852912B (zh) 2017-09-07 2024-08-21 美商銳新醫藥公司 Shp2抑制劑組合物以及治療癌症的方法
JP7447002B2 (ja) 2017-09-11 2024-03-11 クルーゾン・ファーマシューティカルズ・インコーポレイテッド ＳＨＰ２のオクタヒドロシクロペンタ［ｃ］ピロールのアロステリック阻害剤
EP3687997A1 (en) 2017-09-29 2020-08-05 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
BR112020007058A2 (pt) 2017-10-12 2020-10-06 Revolution Medicines, Inc. compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos
BR112020009757A2 (pt) 2017-12-15 2020-11-03 Revolution Medicines, Inc. compostos policíclicos como inibidores alostéricos de shp2
WO2019152454A1 (en) 2018-01-30 2019-08-08 Research Development Foundation Shp2 inhibitors and methods of use thereof
US11498930B2 (en) 2018-02-13 2022-11-15 Blueray Therapeutics (Shanghai) Co., Ltd Pyrimidine-fused cyclic compound, preparation method therefor and application thereof
WO2019165073A1 (en) 2018-02-21 2019-08-29 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
MA52421A (fr) 2018-03-02 2021-01-06 Otsuka Pharma Co Ltd Composés pharmaceutiques
US12138263B2 (en) 2018-03-21 2024-11-12 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof
RU2020133727A (ru) 2018-03-21 2022-04-21 Сучжоу Пухе Биофарма Ко., Лтд. Ингибиторы shp2 и их применение
CN117263942A (zh) 2018-03-21 2023-12-22 传达治疗有限公司 Shp2磷酸酶抑制剂及其使用方法
KR20200143417A (ko) 2018-04-10 2020-12-23 레볼루션 메디슨즈, 인크. Shp2 억제제 조성물, 암을 치료하는 방법 및 shp2 돌연변이를 갖는 대상체를 확인하는 방법
KR102611661B1 (ko) 2018-05-02 2023-12-08 나비레 파르마, 인코퍼레이티드 Ptpn11의 치환된 헤테로사이클릭 억제제
CN116003321A (zh) 2018-05-09 2023-04-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
US20210230300A1 (en) 2018-06-04 2021-07-29 Bayer Aktiengesellschaft Inhibitors of shp2
MA53395A (fr) 2018-07-24 2021-06-02 Otsuka Pharma Co Ltd Composés hétérobicycliques pour inhiber l'activité de shp2
TWI825144B (zh) 2018-08-10 2023-12-11 美商思達利醫藥公司 第二型轉麩醯胺酸酶(tg2)抑制劑
PL3833670T3 (pl) * 2018-08-10 2024-08-19 Navire Pharma, Inc. Pochodne 6-(4-amino-3-metylo-2-oksa-8-azaspiro[4.5]dekan-8-ylo)-3-(2,3-dichlorofenylo)-2-metylopirymidyn-4(3h)-onu oraz powiązane związki jako inhibitory ptpn11 (shp2) do leczenia raka
AR117164A1 (es) 2018-11-30 2021-07-14 Merck Sharp & Dohme Derivados de amino-triazoloquinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso para el tratamiento de diversos tipos de cáncer
AU2019389168A1 (en) 2018-11-30 2021-06-24 Comet Therapeutics, Inc. Pantetheine derivatives and uses thereof
AR117200A1 (es) 2018-11-30 2021-07-21 Syngenta Participations Ag Derivados de tiazol microbiocidas
CN113613724B (zh) 2018-11-30 2024-11-08 葛兰素史克知识产权开发有限公司 可用于hiv疗法的化合物
PY1999867A (es) 2018-11-30 2020-10-19 Syngenta Crop Protection Ag Derivados de tiazol microbiocidas

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012011592A1 (ja) * 2010-07-23 2012-01-26 武田薬品工業株式会社 複素環化合物およびその用途
JP2018517746A (ja) * 2015-06-19 2018-07-05 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物および組成物
WO2017211303A1 (en) * 2016-06-07 2017-12-14 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
WO2018136264A1 (en) * 2017-01-23 2018-07-26 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors

Also Published As

Publication number Publication date
FI3833670T3 (fi) 2024-05-21
US11104675B2 (en) 2021-08-31
WO2020033828A1 (en) 2020-02-13
EP4356973A2 (en) 2024-04-24
IL307361B2 (en) 2024-12-01
TW202019900A (zh) 2020-06-01
IL280701B2 (en) 2024-03-01
IL307361B1 (en) 2024-08-01
US20250188074A1 (en) 2025-06-12
JP7579402B2 (ja) 2024-11-07
EP3833670B1 (en) 2024-04-17
PE20211050A1 (es) 2021-06-04
DK3833670T3 (da) 2024-05-13
CR20210132A (es) 2021-07-20
CO2021003074A2 (es) 2021-06-10
SI3833670T1 (sl) 2024-07-31
PT3833670T (pt) 2024-05-22
SMT202400192T1 (it) 2024-07-09
EP4356973A3 (en) 2024-06-26
US20220041594A1 (en) 2022-02-10
TWI827646B (zh) 2024-01-01
IL307361A (en) 2023-11-01
AU2019319971A1 (en) 2021-03-25
US20200048249A1 (en) 2020-02-13
MX2024001249A (es) 2024-02-14
KR102707409B1 (ko) 2024-09-13
CL2021000355A1 (es) 2021-08-27
LT3833670T (lt) 2024-06-25
PH12021550268A1 (en) 2021-11-03
SA521421205B1 (ar) 2024-11-18
SG11202100199UA (en) 2021-02-25
IL280701A (en) 2021-03-25
CA3109181A1 (en) 2020-02-13
EP3833670A1 (en) 2021-06-16
CN112601750B (zh) 2023-10-31
AU2019319971B2 (en) 2024-11-28
US11945815B2 (en) 2024-04-02
ES2981592T3 (es) 2024-10-09
UA128559C2 (uk) 2024-08-14
BR112021002327A2 (pt) 2021-05-04
HUE067297T2 (hu) 2024-10-28
KR20210043569A (ko) 2021-04-21
PL3833670T3 (pl) 2024-08-19
ZA202101449B (en) 2024-08-28
CN112601750A (zh) 2021-04-02
RS65728B1 (sr) 2024-08-30
JP2023144075A (ja) 2023-10-06
HRP20240861T1 (hr) 2024-10-11
IL280701B1 (en) 2023-11-01
MX2021001608A (es) 2021-07-15

Similar Documents

Publication Publication Date Title
JP7579402B2 (ja) 癌治療用ｐｔｐｎ１１（ｓｈｐ２）阻害剤としての６－（４－アミノ－３－メチル－２－オキサ－８－アザスピロ［４．５］デカン－８－イル）－３－（２，３－ジクロロフェニル）－２－メチルピリミジン－４（３ｈ）－オン誘導体及び関連化合物
JP7044375B2 (ja) Ｐｔｐｎ１１の複素環式阻害剤
JP7297871B2 (ja) Ｐｔｐｎ１１の置換されたヘテロ環式インヒビター
WO2017156397A1 (en) Heterocyclic inhibitors of ptpn11
KR20210003764A (ko) 전사 활성화 단백질의 이미다조피페라진 억제제
JP2022529518A (ja) チロシンキナーゼの複素環式阻害剤
US11466017B2 (en) Heterocyclic inhibitors of PTPN11
HK40039574A (en) Ptpn11(shp2) inhibitors
HK40039574B (en) Ptpn11(shp2) inhibitors
HK40006960B (en) Heterocyclic inhibitors of ptpn11
HK40006960A (en) Heterocyclic inhibitors of ptpn11
CN101528228A (zh) Pde4的双环杂芳基抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220809

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220809

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230713

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230718

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20231128